BACKGROUND: Influenza and HIV are endemic in Nigeria but there is no epidemiological data on the co-infection of influenza A and B among HIV patients. OBJECTIVE: We investigated seasonal influenza A and B, and co-infection among HIV patients on combined antiretroviral therapy (cART) in Lagos, Nigeria. METHODS: In a prospective cross-sectional study, clear sera collected from 174 HIV-positive patients between August and September 2018 were analysed for immunoglobulin M-specific antibodies to seasonal influenza A subtypes H1N1 and H3N2, and influenza B by enzyme immunoassay. RESULTS: A total of 39.7% (69/174) of HIV patients were seropositive for influenza A or B viruses with 84.1% (58/69) being positive for influenza A, 13.04% (9/69) seropositive for both influenza A and B, and only 2.9% (2/69) positive for influenza B mono-infection. Median age was 44 (mean 45, mode 40, range 18-74) years. The 41-50 years age group had the highest seroprevalence (39.1%; 27/69). Seropositivity was highest among women (65.2%; 45/69). A total of 88.4% (61/69) of HIV patients seropositive for influenza A or B were on fixed dose cART, while 73.9% (51/69) were virologically suppressed. Furthermore, 27.5% (19/69) were immunocompromised, of which 21.1% (4/19) were severely immunosuppressed (cluster of differentiation 4 < 200 cells/mm>3). CONCLUSION: Influenza A and B was prevalent among HIV patients on cART, which may predispose them to life-threatening complications. We recommend strong advocacy on the need to reduce the risk of exposure to influenza and for the provision of an influenza vaccine in Nigeria.
BACKGROUND: Influenza and HIV are endemic in Nigeria but there is no epidemiological data on the co-infection of influenza A and B among HIV patients. OBJECTIVE: We investigated seasonal influenza A and B, and co-infection among HIV patients on combined antiretroviral therapy (cART) in Lagos, Nigeria. METHODS: In a prospective cross-sectional study, clear sera collected from 174 HIV-positive patients between August and September 2018 were analysed for immunoglobulin M-specific antibodies to seasonal influenza A subtypes H1N1 and H3N2, and influenza B by enzyme immunoassay. RESULTS: A total of 39.7% (69/174) of HIV patients were seropositive for influenza A or B viruses with 84.1% (58/69) being positive for influenza A, 13.04% (9/69) seropositive for both influenza A and B, and only 2.9% (2/69) positive for influenza B mono-infection. Median age was 44 (mean 45, mode 40, range 18-74) years. The 41-50 years age group had the highest seroprevalence (39.1%; 27/69). Seropositivity was highest among women (65.2%; 45/69). A total of 88.4% (61/69) of HIV patients seropositive for influenza A or B were on fixed dose cART, while 73.9% (51/69) were virologically suppressed. Furthermore, 27.5% (19/69) were immunocompromised, of which 21.1% (4/19) were severely immunosuppressed (cluster of differentiation 4 < 200 cells/mm>3). CONCLUSION: Influenza A and B was prevalent among HIV patients on cART, which may predispose them to life-threatening complications. We recommend strong advocacy on the need to reduce the risk of exposure to influenza and for the provision of an influenza vaccine in Nigeria.
Authors: A Sauerbrei; T Langenhan; A Brandstadt; R Schmidt-Ott; A Krumbholz; H Girschick; H Huppertz; P Kaiser; J Liese; A Streng; T Niehues; J Peters; A Sauerbrey; H Schroten; T Tenenbaum; S Wirth; P Wutzler Journal: Euro Surveill Date: 2014-02-06
Authors: Nathaniel D Lambert; Inna G Ovsyannikova; V Shane Pankratz; Robert M Jacobson; Gregory A Poland Journal: Expert Rev Vaccines Date: 2012-08 Impact factor: 5.217
Authors: Guillermo Domínguez-Cherit; Stephen E Lapinsky; Alejandro E Macias; Ruxandra Pinto; Lourdes Espinosa-Perez; Alethse de la Torre; Manuel Poblano-Morales; Jose A Baltazar-Torres; Edgar Bautista; Abril Martinez; Marco A Martinez; Eduardo Rivero; Rafael Valdez; Guillermo Ruiz-Palacios; Martín Hernández; Thomas E Stewart; Robert A Fowler Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Kondwani C Jambo; Enoch Sepako; Sarah J Glennie; David Mzinza; Neil A Williams; Stephen B Gordon; Robert S Heyderman Journal: PLoS One Date: 2012-06-08 Impact factor: 3.240
Authors: Karen L Laurie; Patricia Huston; Steven Riley; Jacqueline M Katz; Donald J Willison; John S Tam; Anthony W Mounts; Katja Hoschler; Elizabeth Miller; Kaat Vandemaele; Eeva Broberg; Maria D Van Kerkhove; Angus Nicoll Journal: Influenza Other Respir Viruses Date: 2012-04-30 Impact factor: 4.380
Authors: Antonia Ho; Jane Mallewa; Ingrid Peterson; Miguel SanJoaquin; Shikha Garg; Naor Bar-Zeev; Mavis Menyere; Maaike Alaerts; Gugulethu Mapurisa; Moses Chilombe; Mulinda Nyirenda; David G Lalloo; Camilla Rothe; Marc-Alain Widdowson; Meredith McMorrow; Neil French; Dean Everett; Robert S Heyderman Journal: Am J Trop Med Hyg Date: 2018-07-19 Impact factor: 2.345
Authors: Nuha Milad Ashtiwi; Demba Sarr; Tamás Nagy; Z Beau Reneer; Ralph A Tripp; Balázs Rada Journal: Front Immunol Date: 2022-05-18 Impact factor: 8.786